Lapatinib Tablet, Film Coated
Product Images NDC 0480-3237

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Lapatinib (NDC 0480-3237). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Teva Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Chemical Structure (Image 1)

Chemical Structure (Image 1)
Chemical structure diagram of Lapatinib, showing its molecular composition including aromatic rings, chlorinated and fluorinated substituents, and sulfonamide groups, consistent with the approved pharmaceutical compound.*
FDA Label Image

Figure 1 (Image 2)

Figure 1 (Image 2)
A line graph showing cumulative progression-free survival over time (weeks) comparing two treatments: Capecitabine (2,500 mg/m²) and Lapatinib (1,250 mg) plus Capecitabine (2,000 mg/m²). The y-axis represents cumulative progression-free survival, and the x-axis represents time in weeks. The graph includes two curves illustrating differences in survival rates between the treatments over approximately 80 weeks.*
FDA Label Image

Figure 2 (Image 3)

Figure 2 (Image 3)
A Kaplan-Meier curve chart displaying cumulative progression-free survival over time (weeks) comparing two treatments: Lapatinib (1,250 mg) plus Capecitabine (2,000 mg/m²) versus Capecitabine alone (2,500 mg/m²). The chart shows the proportion of patients progression-free on the vertical axis and time in weeks on the horizontal axis.*
FDA Label Image

Figure 3 (Image 4)

Figure 3 (Image 4)
A Kaplan-Meier survival curve chart showing cumulative progression-free survival over time in weeks. The chart compares two treatment groups: Lapatinib (1,500 mg) plus Letrozole (2.5 mg) represented by a solid line, and Letrozole (2.5 mg) alone represented by a dashed line.*
FDA Label Image

Figure 4 (Image 5)

Figure 4 (Image 5)
A Kaplan-Meier survival curve chart showing cumulative progression-free survival over time since randomization in months for three treatment groups: Lapatinib (1,000 mg) plus Trastuzumab and AI, Lapatinib (1,500 mg) plus AI, and Trastuzumab plus AI. The y-axis represents cumulative progression-free survival proportion, and the x-axis represents time in months up to 45 months.*
FDA Label Image

Label 250 mg, 150 Tablets (Image 6)

Label 250 mg, 150 Tablets (Image 6)
Lapatinib Tablets 250 mg film-coated oral tablets label from Teva Pharmaceuticals, Inc. The label includes the NDC 0480-3237-51 and states a package size of 150 tablets. The label provides storage instructions, drug dosing equivalent, and manufacturer details.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.